A major global pharmaceutical firm said its decision to back out of a £1bn research hub partway through construction is because the UK is “not internationally competitive”.
The move by US-based firm Merck, known as MSD across Europe, is the latest setback for Britain, despite Labour having put life sciences as a key pillar to support across business in the new industrial strategy earlier this year.
